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http://www.biomedcentral.com/1472-6882/12/239RESEARCH ARTICLE Open AccessA comparative study on the hepatoprotective
action of bear bile and coptidis rhizoma aqueous
extract on experimental liver fibrosis in rats
Ning Wang1, Yibin Feng1*, Fan Cheung1, Oi-Yee Chow1, Xuanbin Wang1,3,4, Weiwei Su2 and Yao Tong1Abstract
Aim of the study: Bear bile and Coptidis Rhizoma have been used in Chinese medicine with a long tradition in
treating heat-diseases. Both bear bile and Coptidis Rhizoma are used to treat liver diseases in clinical practice of
Chinese Medicine. Since bears are currently endangered, it raises the question whether the use of bear bile is
ethical. To look for substitute for bear bile, the aim of this study is to compare the anti-fibrotic effects of Coptidis
Rhizoma and its major component berberine with the actions of bear bile and its major compound
tauroursodeoxycholic acid on experimental liver fibrosis in rats.
Method: Quality assessment was conducted with high performance liquid chromatography. The experimental liver
fibrosis in rats was induced by carbon tetrachloride, alcohol, and bile duct ligation respectively. The biochemical
criteria in the blood and tissue samples were measured to evaluate the anti-fibrotic properties and underlying
mechanisms of the drugs.
Results: Coptidis Rhizoma Aqueous Extract (CRAE), berberine, and bear bile exerted anti-fibrotic properties on
various liver fibrosis models in rats. CRAE and berberine significantly reduced the peroxidative stress in liver through
increasing the superoxide dismutase enzyme activity. CRAE and berberine were able to excrete bilirubin products
from the liver and protect hepatocytes from cholestatic damage. The effect of CRAE and berberine are comparable
to that of bear bile.
Conclusion: Instead of using bear bile, CRAE and berberine can be potential substitutes in treating liver fibrosis.
Keywords: Coptidis rhizoma, Bear bile, Liver fibrosis, Alternative, Comparative studyBackground
Bear bile can be obtained from the gall bladder of brown
bear (Ursus arctos) and Asiatic black bear (Selenarctos
thibetanus). The creature must be either sacrificed, or
inserted a metal catheter into its gall bladder extract the
bile. Currently in China, there are no legislatures to pro-
hibit the establishment of bear farming to obtain bile.
Many reports concluded that bear farming should be
abolished due to the inhumane treatment of the crea-
tures. [1]. Brown bear and Asiatic black bear are listed
in Convention on International Trade in Endangered
Species of Wild Fauna and Flora (CITES) Appendix I.* Correspondence: yfeng@hku.hk
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reproduction in any medium, provided the orThe use of bear bile in traditional Chinese medicine
conflicts with the morals of animal protection [2]. Based
on the reasons above, it is necessary for the science
community to design systematic, serious and compara-
tive research to get convincing data for substitute for
bear bile.
There are only four sources of alternatives to bear bile
being reported currently. These include bile from other
animals, derivatives from plants, chemical compounds,
and synthetic bear bile. Recently, our research provides
evidence that bear bile can be easily replaced by those of
other animals for certain situations [3]. Despite being an
effective option, the sacrifice of animals is frowned upon
by animal rights activist. The replacement of bear bile
through the use of herbs and plants provides a means
to treat liver fibrosis without harming any animals.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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using alternatives and hold true to the use of bear bile.
It should be an arduous task to replace the bear bile by
product with the same composition, but it is possible to
evidence the comparable therapeutic effect of herbal
substitute with scientific approaches. As of today, deriva-
tives from plant remain as only suggestions and not
proven treatments. The use of Coptidis Rhizoma may be
suggested because of its similarity with bear bile in the
traditional use according to Chinese Medicine theories,
and both Coptidis Rhizoma and bear bile have similar
clinical indications and scientific evidences in treating
liver diseases [4-9]. However, there is no study report-
ing the comparative study on the anti-fibrotic action
of Coptidis Rhizoma and bear bile and their under-
lying mechanism.
Liver fibrosis is an abnormal wound-healing process in
which the connective tissues proliferate under certain
conditions. Several kinds of continuous and chronic liver
injuries could induce liver fibrosis, among which Hepa-
titis B viral infection (HBV) is the main cause of liver
fibrosis in China, while hepatitis C infection and alco-
holic intoxication cause liver fibrosis in the United
States, Europe and Japan [4]. Previous studies on the
pathogenesis of liver fibrosis indicated that activation
of hepatic stellate cells, over-expression and over-
accumulation of extracellular matrix (ECM) protein, and
collagen-like protein in liver tissue may be involved [10].
The treatment of liver fibrosis includes eliminating the
primary disease, modulating the immune system, sup-
pressing liver inflammation, inhibiting the accumulation
of ECM protein, and reducing complications [11].
In this study, we aimed to examine the anti-fibrotic ef-
fect of Coptidis Rhizoma (CR) and its major component
berberine, and compare their pharmacological action
with that of bear bile (BB) and its major compound taur-
oursodeoxycholic acid (TUDCA). Quality assessment of
CR aqueous extract (CRAE) and BB were performed
using HPLC-DAD methods. Three animal models were
established for testing relevant doses of CRAE, berber-
ine, BB and TUDCA, which is obtained from dose
screening of testing drugs. CCl4, Bile duct-ligation (BDL)
and alcohol-fed were introduced to induce experimental
liver fibrosis in rats. Serum aspartate aminotransferase
(AST), alanine transaminase (ALT), and total bilirubin
(TBil) were measured to determine the hepatoprotective
effect of CRAE, berberine, BB, and TUDCA. Tissue
Hydroxyproline (HyP) content was examined to deter-
mine the fibrosis level in liver. Tissue superoxide dismu-
tase (SOD) was determined to elucidate of underlying
mechanism of the drugs. Both negative control and posi-
tive controls (Silymarin) were used in the experiments.
We found both CRAE and berberine significantly atte-
nuated liver fibrosis in rats as well as BB, but notTUDCA. Mechanism studies showed that CRAE and
berberine selectively increased the SOD activity and pro-
moted bilious product excretion, which reduced the oxi-
dative stress of the hepatocytes. Our study reveals that
CRAE and berberine may be the possible alternatives to
bear bile.
Materials and methods
Chemicals and drugs
Tauroursodeoxycholic acid (TUDCA), Silymarin, Berber-
ine (BBR) and Carbon tetrachloride (CCl4) were pur-
chased from Sigma-aldrich (USA); Coptidis Rhizoma
(CR, Huanglian in Chinese) was obtained from the
Chinese Medicine Good Agriculture Practice (GAP) base
for Huanglian in Chongqing, China. The Bear bile (BB)
obtained from Asiatic Black Bear was purchased from
Hang Hing Company (Hong Kong, license No. APO/PL
2384/07).
Sample preparation
To prepare the CR aqueous extract (CRAE), raw materi-
als were cut into small pieces and 50 grams of crude CR
was boiled in 500 mL of distilled C for 1 hour and then
filtered. The filtrate was then evaporated to dryness
and the dry extract powder was collected and stored
at −20°C until used.
Chemical analysis
High Performance Liquid Chromatography (HPLC) with
Photodiode Array (PDA) Detector was conducted to
determine the chemical constitution of CRAE and BB.
To assess the chemical composition of CRAE with con-
ditions as literature reports [5,6] with some modifica-
tions, 10 μL of CRAE (0.5 mg/mL in methanol) was
injected and eluted through RP-C18 column (250 mm x
4.0 mm, 5 μm, Alltech, USA) with mobile phase as
acetonitrile-25 mM potassium dihydrogen phosphate
(25:75). The flow rate was 1.0 mL/min and detection
was performed at 350 nm. An equal volume of berberine
in methanol was injected as standard marker. The con-
jugated bile acids was assessed using A Nova-PackW C18
column (300 mm × 3.9 mm I.D., particle size, 4 μm;
Waters, USA) as solid phase and MeOH-25 mM potas-
sium dihydrogen phosphate (65:35) as mobile phase.
The column was kept at 40°C. The flow rate and detec-
tion wavelength is 0.9 mL/min and 200 nm. Sodium
taurouesodeoxycholate (TUDCA) was injected as stand-
ard marker.Animals
Male KM mice weighing 20 ~ 25 g and male SD rats
weighing 220 ~ 250 g were kept under conditions of con-
trolled temperature (25 + 2 °C) and illumination (12 h light
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laboratory foodstuff and water freely. All experiments were
complied with the international and Chinese guidelines
and approved by the regional ethics committee.Acute liver damage
The acute liver damage mice model was established by
intraperitoneally injecting 3 mg/kg of CCl4 (1:1 mixed
with olive oil) half hour before drug treatment.CCl4-induced liver fibrosis
Liver fibrosis rat model was established by administra-
tion of CCl4. Animals were grouped, and all except the
normal group received 3 mg/kg of CCl4 (1:1 mixed with
olive oil) intraperitoneally twice per week for seven
weeks. Rats in the normal group received 3 mg/kg of
olive oil subcutaneously during the same period.Figure 1 Quality assessment of CRAE and BB by HPLC-DAD method. (Bile duct ligation (BDL)-induced liver fibrosis
Extrahepatic cholestasis was produced by common bile
duct ligation (BDL). In brief, under ether anesthesia, the
common bile duct was ligated with 3–0 silk and sec-
tioned between the ligatures. The midline abdominal in-
cision was closed with catgut. Sham-operated rats had
their bile duct exposed but not ligated or sectioned. All
rats were caged at 24°C with a 12:12 h light–dark cycle,
and were allowed free access to food and water for two
days before the study. All ligated rats were then divided
into six groups. The induction group (BDL rats), normal
group, and sham group was administrated equal volume
of PBS during the period of experiment.
Alcohol fed-induced liver fibrosis
The alcohol fed-induced liver fibrosis model in rats was
established as according to the literature with some
modifications [12]. Briefly, rats in each group, except forA) shows chromatogram of CRAE. (B) shows chromatogram of BB.
Table 1 The dose-dependent effect of BB on AST and
ALT level in CCl4-induced acute liver toxicity in mice
(n = 8, x  s)
Group N Dose(mg/kg) AST(U/I) ALT(U/I)
normal 8 — 99.0 ± 15.8 44.6 ± 10.6
CCl4 8 — 271.3 ± 142.0
△ △ 209.5 ± 153.9△ △
Silymarin 8 100 133.8 ± 49.9 ** 80.4 ± 40.5 *
BB 8 10 202.5 ± 205.5 237.8 ± 383.2
BB 8 30 123.8 ± 17.7 ** 63.9 ± 49.6 **
BB 8 90 119.0 ± 58.6 * 63.9 ± 37.3 **
BB 8 270 123.8 ± 22.0** 45.5 ± 12.0**
BB 8 810 127.3 ± 56.4 ** 59.3 ± 25.3 **
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.
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corn oil (10 mL-25 mg-2 mL) twice every day through
oral gavage (5 mL/kg body weight) for seven weeks. Dur-
ing the same period, animals received respective daily
treatment orally. In the normal group, rats were given
equal volumes of PBS every day.
Treatment Optimal doses of each drug for the treat-
ment of liver fibrosis in animal model were determined
based on the results of acute liver damage model. Rats
in normal, shamed, and model group received 10 mL/kg
of distilled water per day by oral administration, as well
as 120 mg/kg berberine, 600 mg/kg CRAE, 270 mg/kg
BB or 20 mg/kg TUDCA, respectively. 150 mg/kg of
Silymarin was administrated orally to rats as a positive
control. All treatments lasted for seven weeks.
Biochemical analysis
Animals were sacrificed at the end of the experiment by
an overdose of pentobarbitone (Phenobarbital 200 mg/
kg, i.p) immediately. Blood samples were collected and
serum aspartate aminotransferase (AST), alanine trans-
aminase (ALT) and total bilirubin (TBil) were detected
using biochemical auto-analyzer. The results were
normalized by the total protein level in serums. Liver
samples in rats were collected and the tissue proteins
were extracted by homogenization. The Tissue Hydroxy-
proline (HyP) content and Tissue Superoxide Dismutase
(SOD) were measure using commercial detection kits
(Jiancheng Bioengineering Institute, Nanjing, China).
Histological analysis
Livers from rats were removed and fixed in 10% formal-
dehyde buffer for 24 h. Paraffin sections were prepared
and cut into 5 μm thick sections. Sections were stained
with hematoxylin and eosin staining (H&E staining). To
determine the liver injury, we use semi-quantitative
method according to our previous publication and three
individual professional pathologists were invited [5].
A combinational score was provided to each section
based on histologist’s judgments on the grade of severe
hepatocyte cell death, inflammatory cell infiltration and
fibrosis. To further identify the level of fibrosis, five
phases of liver fibrosis were defined according to the lit-
erature. The S0 phase showed no signs of observed fi-
brosis. The S1 phase showed no extension of portal area
fibrosis. The S2 phase exhibited fibrosis occurring in the
portal area with an intact lobule structure. The S3 phase
shows fibrosis associated with a broken lobule structure,
but no signs of cirrhosis. The S4 phase shows fibrosis
and the formation of cirrhosis. Fibrotic area within
1.5 mm2 of each section was measured under the light
microscope. Six sections in each group was randomly
sampled and analyzed under microscope.Statistic analysis
Data were expressed as Data were expressed as mean ±
standard deviation (S.D.) and statistical comparisons
were performed using Student-Newman-Keuls test [13]
using SPSS 11.5.
Results
Quality assessment of CRAE and BB
To evaluate the quality of CRAE and BB, HPLC-DAD
was introduced to quantify the major active compound
in CRAE and BB. According to the China Pharmacopeia
(Edition 2010), berberine was injected as standard
marker of CR, and the yields of epiberberine, palmatine
and coptisine were calculated based on the ratio of their
peak area values to berberine. The chromatogram of
CRAE was shown in Figure 1A and the yields of epiber-
berine, palmatine, coptisine and berberine were 0.47%,
2.54%, 1.77%and 23.05%, respectively, which was consist-
ent with our previous reports [5,6]. Conjugated bile acids
were determined by HPLC-DAD and TUDCA was
injected as standard marker to evaluate the quality of BB
sample. The result showed that TUDCA was the most
abundant component in BB and the yield of TUDCA in
BB was 7.84%, which was consistent with our previous
report [3].
Optimization of drugs dose
To better understand the effect of different drug agents,
the dose-dependent effect of each drug should be evalu-
ated. CCl4-induced acute liver damage in mice was used
as animal model to study the dose dependent effect of
BB. The results showed that BB had potent effect on re-
ducing the serum’s AST and ALT level. The optimized
dose for the effect was about 270 mg/kg (Table 1).
Since TUDCA was the major active compound in BB,
the dose of TUDCA was determined subject to its pro-
portion in BB. Calculated by HPLC, TUDCA comprises
about 7.84% of BB as shown in Figure 1, so the
Table 2 Impact of drug intervention on the animal daily behavior in CCl4-induced liver fibrotic rats (n = 7, x  s)
Index Body weight (g) Water drinking (mL per rat) feeding (g per rat)
Group dose
mg/kg
n D0 D14 D35 D49 D0 D14 D35 D49 D0 D14 D35 D49
Normal — 7 195 ± 6.1 303 ± 10.0 368 ± 41.2 416 ± 25.4 41.0 ± 1.4 60.0 ± 21.2 43.1 ± 11.5 61.4 ± 0.9 21.8 ± 2.0 37.6 ± 0.6 25.7 ± 0.2 23.8 ± 0.2
Model — 7 198 ± 9.5 267 ± 40.3△△ 288 ± 15.6△△ 302 ± 17.2△△ 36.7 ± 2.4 41.7 ± 9.4 35.0 ± 4.7 26.8 ± 2.5△ 18.1 ± 1.2 29.5 ± 2.4 20.2 ± 4.5 17.6 ± 7.4
Silymarin 150 7 192 ± 8.3 260 ± 40.4 293 ± 46.0 306 ± 55.1 47.0 ± 9.9 33.8 ± 5.3 27.5 ± 0.0 22.9 ± 7.7 21.7 ± 2.3 22.3 ± 9.8 17.3 ± 4.1 19.5 ± 5.0
Berberine 120 7 195 ± 5.3 277 ± 23.3 292 ± 33.4 309 ± 28.9 41.0 ± 1.4 37.5 ± 0.0 40.4 ± 4.1 34.3 ± 7.8 19.1 ± 2.9 25.3 ± 0.2 20.1 ± 1.1 19.5 ± 0.5
CRAE 600 7 195 ± 7.5 271 ± 24.6 300 ± 30.8 318 ± 35.7 34.0 ± 8.5 35.6 ± 2.7 34.4 ± 0.9 28.3 ± 4.7 16.1 ± 0.0 25.3 ± 3.3 17.8 ± 4.1 19.3 ± 1.2
Bear bile 200 7 201 ± 1.3 285 ± 21.4 321 ± 19.1 358 ± 40.7 33.0 ± 1.4 31.9 ± 9.7 36.3 ± 7.1 31.2 ± 3.5 19.0 ± 0.6 24.8 ± 3.7 22.5 ± 2.2 19.9 ± 0.3
TUDCA 20 7 194 ± 8.8 278 ± 18.1 296 ± 22.3 320 ± 28.2 41.5 ± 3.5 31.3 ± 8.8 37.1 ± 7.7 26.3 ± 8.8 16.2 ± 6.8 23.7 ± 0.3 15.3 ± 2.1 18.9 ± 2.8
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with normal group.
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Table 3 Impact of drug intervention on the animal daily behavior in bile duct ligation-induced liver fibrotic rats (n = 7, x  s)
Index Body weight (g) Water drinking (mL per rat) feeding (g per rat)
group dose
mg/kg
n D0 D14 D21 D28 D0 D14 D21 D28 D0 D14 D21 D28
Normal — 7 207 ± 12.0 328 ± 9.6 382 ± 12.1 389 ± 17.7 37.5 ± 0.0 56.9 ± 8.0 53.1 ± 2.7 51.3 ± 8.8 32.3 ± 11.1 31.1 ± 18.4 32.8 ± 2.4 33.8 ± 0.7
Sham — 7 214 ± 5.4 321 ± 18.9 384 ± 26.2 389 ± 28.3 54.4 ± 6.2 60.0 ± 14.1 60.6 ± 4.4 62.5 ± 7.1 38.4 ± 0.7 34.0 ± 3.0 32.0 ± 0.0 27.1 ± 5.1
Model — 7 213 ± 7.8 290 ± 16.2△△ 332 ± 18.2△△ 338 ± 26.0△△ 41.3 ± 1.8 74.7 ± 1.9 54.0 ± 5.7 48.3 ± 11.8 8.7 ± 3.9△△ 27.1 ± 1.6 27.7 ± 3.0 26.2 ± 1.9△△
Silymarin 150 7 210 ± 6.2 260 ± 24.4 289 ± 15.8 291 ± 15.2 57.4 ± 1.9 85.0 ± 49.5 72.3 ± 0.9* 59.3 ± 3.8* 8.3 ± 2.7 26.9 ± 4.6 22.9 ± 0.4 21.0 ± 0.6
Berberine 120 7 210 ± 6.2 294 ± 29.9 342 ± 31.0 340 ± 32.0 36.1 ± 0.2 76.3 ± 23.0 78.8 ± 3.1** 62.5 ± 7.1** 9.4 ± 1.0 25.7 ± 3.9 28.1 ± 1.9 28.9 ± 3.0
CRAE 600 7 208 ± 6.0 275 ± 25.2 320 ± 3.5 324 ± 2.4 55.0 ± 14.1 70.8 ± 8.2 75.8 ± 5.9** 61.3 ± 15.9* 7.8 ± 1.7 21.6 ± 11.0 28.6 ± 3.9 28.7 ± 1.3
Bear bile 200 7 207 ± 7.5 293 ± 38.5 331 ± 60.5 345 ± 64.7 34.4 ± 0.9 81.3 ± 1.8 75.6 ± 2.7** 72.5 ± 10.6** 8.2 ± 2.2 24.6 ± 1.2 28.2 ± 1.9 29.4 ± 0.8
TUDCA 20 7 212 ± 5.5 279 ± 30.1 311 ± 58.9 307 ± 72.5 30.1 ± 5.5 76.7 ± 28.3 78.3 ± 11.8** 63.3 ± 18.9* 6.9 ± 2.6 24.2 ± 1.3 26.3 ± 2.1 24.8 ± 4.6
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with normal group; *p < 0.05 when compared with model group; **p < 0.01 when compared with model group.
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Table 4 Impact of drug intervention on the animal daily behavior in alcohol fed-induced liver fibrotic rats (n = 7, x 
Index Body weight (g) Water drinking (mL per rat) eding (g per rat)
Group dose
mg/kg
n D35 D42 D49 D56 D35 D42 D49 D56 5 D42 D49 D56
Normal — 7 399 ± 24.8 391 ± 27.6 435 ± 15.4 440 ± 13.9 33.8 ± 8.84 48.1 ± 0.88 42.5 ± 8.84 44.1 ± 0.18 .5 ± 2.81 30.6 ± 7.78 27.2 ± 2.83 28.5 ± 2.76
Model — 7 296 ± 33.6△△ 272 ± 30.1△△ 293 ± 33.8△△ 326 ± 49.4△△ 39.3 ± 5.48 37.0 ± 8.31 37.4 ± 4.40 35.8 ± 15.8 .8 ± 3.87 17.7 ± 6.74 16.3 ± 6.07 21.7 ± 5.34
Silymarin 150 7 321 ± 33.3 317 ± 47.9** 357 ± 45.4** 378 ± 43.1** 41.3 ± 17.7 49.2 ± 13.0* 55.3 ± 0.47** 56.0 ± 6.66* .2 ± 6.08 13.8 ± 8.22 23.4 ± 1.61 25.0 ± 0.08
Berberine 120 7 278 ± 27.1 281 ± 30.7 296 ± 31.3 304 ± 35.8 31.2 ± 5.07 42.5 ± 15.2 34.1 ± 2.79 29.8 ± 3.06 .0 ± 6.28 14.6 ± 2.31 19.0 ± 6.15 18.1 ± 3.20
CRAE 600 7 287 ± 18.9 280 ± 28.3 303 ± 30.5 316 ± 42.8 36.6 ± 2.88 40.9 ± 7.1 33.4 ± 15.16 37.3 ± 15.8 .6 ± 3.53 14.9 ± 4.33 16.6 ± 6.61 24.2 ± 18.98
Bear bile 200 7 279 ± 28.0 263 ± 28.3 279 ± 35.4 302 ± 44.8 29.6 ± 6.07 41.5 ± 12.4 31.4 ± 11.20 35.9 ± 11.0 .6 ± 5.49 21.1 ± 13.6 17.2 ± 5.74 21.4 ± 4.96
TUDCA 20 7 308 ± 48.2 291 ± 56.7 324 ± 30.6 362 ± 30.5 32.5 ± 0.35 42.5 ± 15.9 40.5 ± 7.42 37.0 ± 4.24 .8 ± 3.32 24.3 ± 11.8 22.3 ± 3.59 20.6 ± 1.31
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with normal group; *p < 0.05 when compared with model group; **p < 0.01 when com red with model group.
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20 mg/kg. Based on our previous study [5], the opti-
mized dose of CRAE and berberine were 600 mg/kg and
120 mg/kg, respectively.
Assessment of modeled animal behaviors with treatment
of different agents
Frequent assessments were performed to monitor the
animal behaviors after treatment of different agents. The
body weight, food intake and water drinking were moni-
tored on weekly basis. The results show significant loss
of body weight in rats with liver fibrosis induced by
either CCl4, BDL, alcohol (Tables 2, 3 & 4). The drug
treatments could not attenuate the body weight loss in
modeled rats. However, in alcohol-induced liver fibrotic
rats, silymarin restored the body weight significantly
(Table 4). There were no significant changes on the
weight loss of modeled rats between the treatment of BB
and CRAE (p > 0.05). Interestingly, we found that both
CRAE and BB could increase water consumption in
bile-duct ligation-induced liver fibrotic rats (p < 0.05,
Table 3), while there’s no significant effect of the two
agents on water drinking in the other two liver fibrosisFigure 2 The effect of drug intervention on serum AST, ALT and TBil
CCl4-induced liver fibrosis in rats. (B) shows AST, ALT and TBil level in bile d
level in alcohol induced liver fibrosis in rats. △p < 0.05, △△p < 0.01 when co
with model group.models (p > 0.05, Tables 2 and 4). Considering that
increasing drinking may facilitate the toxic bilirubin
excretion, the effect of CRAE and BB on the water con-
sumption may be of benefit for the recovery of liver
fibrosis in modeled rats. Neither of the drug treatments
had any effect on the food intake of the specimens.The effect of drug intervention on the hepatobiliary
function of rats with liver fibrosis
Significant elevation of serums AST and ALT could be
observed in rats with liver fibrosis induced by CCl4, BDL
or alcohol fed, which indicated chronic liver damages in
model animals (p < 0.05, Figure 2 A&B&C). Increased
TBil level indicated that liver fibrosis induced by CCl4,
BDL and alcohol might also disrupted the normal struc-
ture of bile duct and block the bilirubin excretion (p <
0.05, Figure 2 A&B&C). It was observed that in rats with
liver fibrosis induced by CCL4 or BDL, drugs interven-
tion had no effect on the elevated levels of ALT activity
in serums (p > 0.05). However, significant suppression
of drug intervention on serum AST activities could be
found (p < 0.05, Figure 2 A&B). The decrease in elevatedlevel in liver fibrotic rats. (A) shows AST, ALT and TBil levels in
uct ligation-induced liver fibrosis in rats. (C) shows AST, ALT and TBil
mpared with normal group; *p < 0.05, **p < 0.01 when compared
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either CRAE or BB on the hepatocyte. There was no sig-
nificant differential action on ALT/AST activities in rats
treated with CRAE or BB (p > 0.05 when comparison
was made between CRAE and BB). Decreased serum
TBil level was observed in rats treated with either CRAE
or BB (Figure 2 A&B&C). Consistent reduction of TBil
level in serum could be observed in three animal models
with drugs intervention. The global effective action of
CRAE and BB on TBil cleavage indicated that TBil
cleavage might be the more dominant mechanism in
CRAE and BB’s hepatoprotective action in experimental
liver fibrosis in rats.
The effect of drug intervention on hepatic fibrosis in rats
Significant induction on the Hyp content, the biomarker
of liver fibrosis in tissue, was observed (p < 0.05). CCl4,
BDL and alcohol could induce the up-regulation of Hyp
content in liver, indicating that these interventions could
successfully induce hepatic fibrosis. Drug intervention
could reduce the Hyp content in modeled rats (p < 0.05).
The effect of CRAE (or Berberine) is comparable with
BB (or TUDCA) in treating liver fibrosis induced by
CCl4 (p > 0.05). However, it was observed that BB
(TUDCA) might exhibit better effect in inhibiting Hyp
content than CRAE (or Berberine) did in hepatic fibrosis
though no statistical significance could be found (p >
0.05). The results were shown in Figure 3A. Six sec-
tions from each group were selected randomly and the
histological study was conducted by three individualFigure 3 The effect of drug intervention on the tissue HyP content an
intervention could reduce the HyP content in the liver of rats with fibrosis
could recover the SOD activity in liver. △p < 0.05, △△p < 0.01 when compar
model group.examiners. The level of fibrosis was evaluated, and the fi-
brotic area within 1.5 mm2 of each section was measured
under the light microscope. Our results showed that
CCl4, BDL and alcohol could successfully induce fibro-
genesis in rats (p < 0.05 when compared with normal
group). The liver fibrosis was mildly attenuated by the
presence of silymarin and TUDCA (p > 0.05). Significant
therapeutic action of CRAE and BB was observed in the
respective group of rats (p < 0.05). Berberine exhibited
similar anti-fibrotic effect to CRAE (p > 0.05). The results
were shown in Figure 4 and Tables 5, 6 and 7.
The anti-oxidative action of drug intervention on liver
fibrosis in rats
Significant drop of tissue SOD levels could be observed
in liver fibrotic rats induced by CCl4, BDL and alcohol
(Figure 4). The reduction of SOD levels in liver might
lead to high contents of peroxides, chronic inflammation
and destruction to the liver, which was the major cause
of hepatic fibrosis. Recovery of SOD levels in liver was
observed in rats with intervention of CRAE, berberine
and BB (p < 0.05). However, the major active compound
in BB, TUDCA failed to restore the SOD levels in rats
with liver fibrosis (p > 0.05), which indicated that a dif-
ferent mechanism might be involved in the anti-fibrotic
action of TUDCA (Figure 3B).
Histological observation
Histological analysis was performed by three individual
pathologists to analyze the section. Severe hepaticd SOD activity in liver fibrotic rats. (A) shows that drug
induced by CCl4, BDL and alcohol. (B) shows that drug intervention
ed with normal group; *p < 0.05, **p < 0.01 when compared with
Figure 4 Histological observation on the liver sections from fibrotic rats with or without drug intervention. (A) shows sections in rats
with liver fibrosis induced by CCl4. (B) shows sections in rats with liver fibrosis induced by bile duct-ligation. (C) shows sections in rats with
liver fibrosis induced by alcohol. All the drugs could have potent action of preventing liver fibrosis induced by alcohol.
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CCl4, BDL or alcohol in rats (p < 0.05). Most of the
drugs exhibited potent therapeutic effect regarding the
combined scores based on the examination of hepato-
cyte death, inflammatory cell infiltration and fibrosis(p < 0.05 in most of the cases). It was observed that
both CRAE/Berberine and Bear bile/TUDCA could
completely combat the liver fibrosis induced by alcohol
(p < 0.05, Table 8), while in rats with hepatic fibrosis by
CCl4 and BDL, the agents exhibited differential effects.
Table 5 Analysis on effect of drug intervention against
fibrogenesis induced by CCl4 in rats (n = 7, x  s)
Group Sample
(n)
Fibrosis phase Fibrotic area within
1.5 mm2(mm2)S0 S1 S2 S3 S4
Nomral 7 7 0 0 0 0 0
Model 7 0 0 2 4 1 0.090 ± 0.021△△
Silymarin 7 0 2 3 2 0 0.067 ± 0.046
Berberine 7 0 3 2 2 0 0.041 ± 0.020**
CRAE 7 0 2 3 2 0 0.056 ± 0.021*
Bear Bile 7 0 3 3 1 0 0.048 ± 0.046*
TUDCA 7 0 2 3 0 2 0.065 ± 0.047
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.
Table 7 Analysis on effect of drug intervention against
fibrogenesis induced by alcohol fed in rats (n = 7, x  s)
Group Samplev
(n)
Fibrosis Phase Fibrotic area within
1.5 mm2(mm2)0 1 2 3 4
Nomral 7 7 0 0 0 0 0
Model 7 0 0 1 4 2 0.52 ± 0.23 △△
Silymarin 7 0 0 6 1 0 0.27 ± 0.10**
Berberine 7 0 0 5 2 0 0.34 ± 0.18*
CRAE 7 0 2 4 1 0 0.28 ± 0.14**
Bear Bile 7 0 2 4 1 0 0.26 ± 0.12**
TUDCA 7 1 6 0 0 0 0.14 ± 0.049**
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.
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effect on chemical toxin CCl4-induced hepatic damage
and fibrosis (p < 0.05, Table 9); and CRAE and berberine
showed potent action on BDL-induced fibrosis (p < 0.05,
Table 10).Discussion
Bear bile has been used as a remedy in Chinese medicine
for more than thousands years. Bear bile was also widely
used in the Chinese Medicine formulae by practitioners
during their clinical practice. According to the China’s
State Pharmacopoeia (1995 edition), 28 medicines con-
tained bear bile, indicating its frequent use in Chinese
medicine [14]. However, the use of bear bile has received
various criticisms in the recent years. From the eco-
logical standpoint, obtaining bile from wild or farmed
bears undoubtedly endangers the species to the brink of
extinction. The establishment of unethical bear farming
also brings about pain and unexpected diseases to the
animal. Most of all, there are many who are worriedTable 6 Analysis on effect of drug intervention against
fibrogenesis induced by bile duct-ligation in rats
(n = 7, x  s)
Group Sample
(n)
Fibrosis phase Fibrotic area within
1.5 mm2(mm2)0 1 2 3
Normal 7 7 0 0 0 0
Shamed 7 7 0 0 0 0
Model 7 0 2 1 4 0.88 ± 0.46△△
Silymarin 7 0 3 2 2 0.62 ± 0.21*
Berberine 7 0 4 2 1 0.38 ± 0.25**
CRAE 7 0 4 2 1 0.55 ± 0.21*
Bear Bile 7 0 5 1 1 0.32 ± 0.19**
TUDCA 7 0 3 1 3 0.61 ± 0.32
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.that the use of animal products brings about cross-
contamination of infectious diseases to the human popu-
lation [15]. China’s State Pharmacopoeia, starting with
the 2010 edition, no longer includes any medicine whose
ingredients are derived from endangered wild animals
including bear bile. A suitable alternative for bear bile is
of paramount concern.
Extensive studies have indicated that bear bile in Chin-
ese Medicine may be possible to have some alternatives
in herbal or chemical remedies, or products from do-
mestic animals [2,16]. Some studies have found that the
similarities pharmacological actions on rabbit bile and
bear bile [17]. It was also reported that both bear and
pig bile solutions exert similar anti-inflammatory, anti-
convulsive, and analgesic action [18]. TUDCA, the char-
acteristic composition of bear bile, has been successfully
synthesized and used as a commercial product for the
treatment of liver diseases as well as its unconjugated
form, Ursodeoxycholic acid (UDCA) [19]. A recent
study reported that Scutellaria baicalensis Georgi,
Huangqin in Chinese, exhibited anti-inflammatory
action which indicated its potential as an alternative of
bear bile [18]. Bear Bile is a traditional Chinese MedicineTable 8 Semi-quantitative histological analysis on effect
of drug intervention against liver fibrosis induced by
Alcohol in rats (n = 7, x  s)
Group Hepatocyte
death
Inflammatory
cell infiltration
Fibrosis Combined
score
Normal 0.3 ± 0.2 3.0 ± 0.1 0.1 ± 0.1 0.3 ± 0.1
Model 4.1 ± 0.7△△ 3.3 ± 0.6△△ 4.3 ± 0.7△△ 4.0 ± 0.6△△
Sylimarin 1.5 ± 0.7** 1.6 ± 0.5** 3.2 ± 0.5 2.6 ± 0.5*
BBR 1.3 ± 0.3** 1.4 ± 0.5** 1.8 ± 0.3** 2.2 ± 0.5**
CRAE 1.5 ± 0.7** 1.3 ± 0.6** 2.2 ± 0.5** 2.5 ± 0.4*
BB 1.6 ± 0.5** 1.3 ± 30.5** 1.2 ± 0.4** 2.0 ± 0.4**
TUDCA 0.9 ± 0.4** 0.7 ± 0.3** 0.8 ± 0.3** 1.0 ± 0.4**
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.
Table 9 Semi-quantitative histological analysis on effect
of drug intervention against liver fibrosis induced by
CCl4 in rats(n = 7, x  s)
Group Hepatocyte
death
Inflammatory
cell infiltration
Fibrosis Combined
score
Normal 0.8 ± 0.3 0.3 ± 0.2 0.3 ± 0.2 0.5 ± 0.1
Model 5.6 ± 0.9△△ 3.9 ± 0.4△△ 3.3 ± 0.6△△ 4.8 ± 0.7△△
Sylimarin 3.9 ± 0.2* 2.8 ± 0.6* 2.3 ± 0.6 3.0 ± 0.9*
Berberine 3.5 ± 0.4* 3.1 ± 0.4 2.0 ± 0.5* 3.0 ± 0.6*
CRAE 3.8 ± 0.4* 3.0 ± 0.3* 2.1 ± 0.4* 3.2 ± 0.5*
Bear Bile 3.1 ± 0.3** 2.7 ± 0.7* 2.4 ± 0.5 2.8 ± 0.5**
TUDCA 4.3 ± 0.7 3.5 ± 0.4 2.8 ± 0.2 4.1 ± 0.4
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.
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relieving toxin, stopping endogenous win to arrest
convulsion and clearing liver fire to improve eyesight
[2]. Bear bile powder as an individual product has been
used to treat liver diseases in China for many years. Its
active compound TUDCA was developed to protect the
liver in clinics though some adverse effects have been
reported [20]. Coptidis Rhizoma belongs to the same
category with bear bile according to Chinese Medicine
theories, and has been shown to benefit eye function in
some ancient Chinese medical books [2]. The property
of Coptidis Rhizoma in treating eye diseases is similar to
that of bear bile, and studies in our group have exhibited
the beneficial effect of Coptidis Rhizoma on acute
and chronic liver injury [5,6]. These observations sup-
ported Coptidis Rhizoma as an alternative for bear
bile as a medication in treating liver diseases. How-
ever, Chinese Medicine is a very complicated medical
system. The medication used by Chinese Medicine prac-
titioners, called Chinese Medicines in Hong Kong, is
composed of herbs, animal products and minerals.Table 10 Semi-quantitative histological analysis on effect
of drug intervention against liver fibrosis induced by BDL
in rats(n = 7, x  s)
Group Hepatocyte
death
Inflammatory
cell infiltration
Fibrosis Combined
score
Normal 0.5 ± 0.3 0.3 ± 0.3 0.5 ± 0.1 0.5 ± 0.3
Shamed 0.8 ± 0.3 0.7 ± 0.4 0.5 ± 0.3 0.8 ± 0.3
Model 4.7 ± 0.8△△ 4.7 ± 0.4△△ 5.5 ± 0.7△△ 4.8 ± 0.6△△
Sylimarin 3.5 ± 0.3* 4.4 ± 0.9 4.5 ± 0.6 4.2 ± 0.5
Berberine 2.4 ± 0.5** 2.3 ± 0.7** 2.7 ± 0.7** 2.5 ± 0.6**
CRAE 2.7 ± 0.4** 3.4 ± 0.9* 3.3 ± 0.3** 3.0 ± 0.3**
Bear Bile 3.9 ± 0.1 3.5 ± 0.4** 3.3 ± 0.6** 3.8 ± 0.4*
TUDCA 2.8 ± 0.3** 3.7 ± 0.2** 3.6 ± 0.2** 3.4 ± 0.2**
△p < 0.05 when compared with normal group; △△p < 0.01 when compared with
normal group; *p < 0.05 when compared with model group; **p < 0.01 when
compared with model group.Each Chinese Medicine medication is a mixture with
multiple components, and is considered to have various
therapeutic effects against different diseases. In general,
Chinese Medicine practitioners use medical composite
formulae in their clinical practices, both Bear Bile and
Coptidis Rhizoma could be used in formulae or as a sin-
gle medication, but it is not reasonable to simply replace
bear bile with Coptidis Rhizoma in Chinese Medicine
formulae. Based on our current observations, we could
only draw a conclusion that Coptidis Rhizoma has com-
parable anti-fibrotic action with bear bile, and it might
be applicable to use Coptidis Rhizoma as an alternative
when bear bile is applied in the form of single medica-
tion to treat liver fibrosis. Whether Coptidis Rhizoma
could be use in treating other diseases as bear bile does
needs further investigation, and more comprehensive
studies should be conducted before concluding that Cop-
tidis Rhizoma could replace bear bile in clinical practice.
As a principal active compound in Coptidis Rhizoma,
berberine has lots of pharmacological properties, includ-
ing anti-microbial [21], anti-inflammatory [22] anti-
hypertensive [23], anti-diabetic [24], anti-hyperlipidemic
activities [25]. As a commercial product, berberine
chloride is conventionally used for the treatment of bac-
terial diarrhea, intestinal parasitic infections, and ocular
trachoma infections. Some recent studies reported the
anti-fibrotic properties of berberine, indicated its poten-
tial for the treatment of chronic liver diseases. It was
reported that berberine could attenuate the liver fibrosis
induced by multiple hepatotoxic factors in rats [26].
In vitro study revealed that berberine inhibited the
hepatic stellate cell proliferation via arresting the cell
cycle at G1 phase [27]. In our study, we found that
berberine selectively increased the activity of SOD,
whose function was to reduce lipid hydroperoxides to
their corresponding alcohols and to reduce free hydro-
gen peroxide to water [28]. This indicated that berberine
protected liver from oxidative damage and therefore
reduced liver fibrosis. In our previous publications, we
have investigated the effect of Coptidis Rzhioma and
berberine on acute and chronic liver injury [5-7]. Copti-
dis Rzhioma and berberine exhibited protective effect on
acute and chronic liver injury in animal models. And we
also studied the underlying mechanism in vitro in our
previous study [6], we found that Coptidis Rzhioma and
berberine could up-regulate SOD to scavenge oxidative
stress, which activates Erk1/2 and induces apoptosis in
hepatocytes. As constitutive and chronic injury has been
considered as the major cause of liver fibrosis, we con-
tinued to focus on the effect of SOD in this study. We
also detected some anti-oxidative related molecules and
enzymes (Data not shown). However, we found that only
SOD was elevated by Coptidis Rzhioma and Bear Bile.
So we drew a conclusion that SOD should at least take
Figure 5 Illustrated overview for this study.
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We could not conclude that it is the unique mechanism
since Chinese Medicine should be a complex and multi-
target system. However, from our results, SOD up-
regulation should make it count. The possible mechan-
ism involved is as shown in Figure 5. Moreover, reduced
TBil levels in serum indicated that berberine was able
to excrete the bilious product and prevent the hepato-
cyte damage induced by bilious product accumulation.
These observations draw light on berberine’s potential
as a therapeutic agent for both cholestatic and non-
cholestatic liver fibrosis and can be also alternative agent
to bear bile.
Our research demonstrated that CRAE and berberine
had better effects than bear bile and TUDCA in liver
fibrosis animal models. In addition, CRAE is under the
same category of bear bile in Chinese Medicines, thus
CRAE and berberine as the substitutes for bear bile for
liver fibrosis are supported by the traditional reason and
scientific evidences.Conclusion
A comparative study on the hepatoprotective action of
CRAE and bear bile on experimental liver fibrosis in rats
was conducted. Berberine and TUDCA, as the main
component of CRAE and bear bile respectively, were
also included in this study to evaluate their anti-fibrosis
activity. We also observed that CRAE, berberine, and
bear bile exerted anti-fibrotic properties on the liver of
rats. CRAE and berberine reduced the peroxidative
stress in liver through increasing the SOD enzyme activ-
ity. CRAE and berberine were capable of facilitating
harmful bilious product excreted by liver and protecting
hepatocyte from cholestatic damage. The anti-fibrotic
action of CRAE and berberine was comparable to
bear bile on the all three experimental animal models.
CRAE and its major component berberine had the
most potential to replace bear bile for the treatment of
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